Nevertheless, these few trials with davalintide illustrate how the calcitonin receptor system may constitute a target for the treatment of obesity and associated metabolic conditions such as NAFLD. This evidence concerns the gene CALCR and obesity due to melanocortin 4 receptor deficiency.